Related Experiment Video
Updated: May 10, 2025
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
Advancing pancreatic cancer therapy by mesothelin-specific nanobody conjugation
Soyeon Yi1, Kyunghee Noh1,2, Hyeran Kim1
1Bionanotechnology Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), 125 Gwahak-ro, Yuseong-gu, Daejeon, 34141, Republic of Korea.
Abstract:
Pancreatic adenocarcinoma (PAAD) is highly challenging to treat due to its poor prognosis and limited effective treatment options. Liposomal nanotechnology has emerged as a promising drug delivery platform in oncology, but existing liposomal therapies face limitations such as systemic toxicity, insufficient tumor selectivity, and low target specificity. Mesothelin (MSLN), an antigen overexpressed in PAAD, has attracted attention as a potential target for precision therapy. Here, we present the development of an anti-MSLN nanobody (D3 Nb) with high binding affinity (KD = 2.2 nM) that can selectively bind to MSLN-positive cancer cells. Structural analysis revealed that hydrophobic and hydrogen bonds within the complementary determining region (CDR) of D3 Nb promote strong binding to MSLN, leading to significant inhibition of AKT/NF-κB signaling and downregulation of fibronectin 1 (FN1) and twist1, key drivers of PAAD oncogenicity. In vivo studies confirmed that D3 Nb alone inhibits tumor progression. Furthermore, selective delivery to MSLN-positive tumors in combination with gemcitabine-loaded liposomes (D3-LNP-GEM) significantly improved cytotoxicity and promoted tumor regression. These findings highlight the potential of the D3-LNP-GEM platform as a novel targeted therapy for MSLN-expressing malignancies, showing promising efficacy in preclinical models and paving the way for continued clinical evaluation.
Insights
Researchers developed a targeted therapy for pancreatic cancer using an anti-mesothelin nanobody and gemcitabine liposomes. This D3-LNP-GEM platform shows promise for treating MSLN-expressing tumors by improving efficacy and reducing progression.
Area of Science:
- Oncology
- Nanotechnology
- Molecular Biology
Background:
- Pancreatic adenocarcinoma (PAAD) presents significant treatment challenges due to poor prognosis and limited therapeutic options.
- Existing liposomal drug delivery systems in oncology suffer from systemic toxicity and lack tumor selectivity.
- Mesothelin (MSLN) is overexpressed in PAAD, making it a promising target for precision cancer therapy.
Purpose of the Study:
- To develop and characterize a novel anti-MSLN nanobody (D3 Nb) for targeted delivery in PAAD.
- To evaluate the therapeutic potential of D3 Nb alone and in combination with liposomal gemcitabine (D3-LNP-GEM).
- To investigate the mechanism of action of D3 Nb in inhibiting PAAD oncogenic pathways.
Main Methods:
- Development and characterization of an anti-MSLN nanobody (D3 Nb) with high binding affinity.
- Structural analysis of D3 Nb-MSLN interactions.
- In vitro assessment of signaling pathway inhibition (AKT/NF-κB) and oncogene downregulation (FN1, twist1).
- In vivo efficacy studies of D3 Nb and D3-LNP-GEM in preclinical PAAD models.
Main Results:
- D3 Nb demonstrated high binding affinity (KD = 2.2 nM) and selective binding to MSLN-positive cancer cells.
- D3 Nb inhibited AKT/NF-κB signaling and downregulated key PAAD oncogenes FN1 and twist1.
- D3 Nb alone showed tumor progression inhibition in vivo.
- D3-LNP-GEM significantly enhanced cytotoxicity and promoted tumor regression in MSLN-positive tumors.
Conclusions:
- The D3 Nb exhibits potent anti-cancer activity through targeted inhibition of MSLN.
- The D3-LNP-GEM platform offers a novel targeted therapy with improved efficacy for MSLN-expressing malignancies.
- This approach shows significant preclinical promise for advancing PAAD treatment strategies.
More Related Videos
08:35Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
